OTOCALM Ear Drops
1. Disclaimer
This commentary is provided for general educational and pharmaceutical-information purposes only. It is not a substitute for the official product leaflet, professional medical advice, diagnosis, or treatment. The formulation, labeling, indications, dosing instructions, and regulatory status of a medicine may vary between countries and may change over time.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
Particular care is required with otic preparations because their safety depends on the condition of the tympanic membrane. Otocalm should not be used when tympanic membrane perforation is known or suspected unless specifically directed by an appropriately qualified healthcare professional.
2. Summary
Otocalm Ear Drops is an otic solution containing phenazone (antipyrine) 5% w/w and chlorbutol (chlorobutanol) 1% w/w. It is marketed by Pharco Pharmaceuticals in a 10 mL dropper bottle and is classified as an otic analgesic/antiseptic combination. The product is intended primarily for symptomatic relief of ear pain in selected conditions when the tympanic membrane is intact, and it may be used as an adjunct to systemic antibiotic treatment of otic infections when appropriate.
Otocalm does not replace appropriate antimicrobial treatment when a bacterial ear infection requires antibiotics, and it should not be used in the presence of a perforated tympanic membrane.
3. Brand Name
Otocalm® Ear Drops
Pack size: 10 mL
Current Egyptian medicine listings identify Otocalm Ear Drops 10 mL as a Pharco product containing chlorobutanol + phenazone.
4. Category
Pharmacological category: Otic analgesic and antiseptic combination.
International references classify the phenazone/chlorobutanol combination under otological preparations containing analgesic/anesthetic agents.
5. Active Ingredient
Each Otocalm formulation marketed in Egypt is identified as containing:
- Phenazone (Antipyrine): 5% w/w
- Chlorbutol (Chlorobutanol): 1% w/w
Phenazone is a pyrazolone analgesic, while chlorobutanol has antimicrobial activity and has also been used as a local anesthetic/preservative in pharmaceutical preparations.
6. Pharmaceutical Form & Strength
Dosage form: Ear drops, solution
Route: Otic
Pack size: 10 mL
Strength:
- Phenazone 5% w/w
- Chlorbutol 1% w/w
The product is a solution, not a suspension, and therefore does not require shaking or reconstitution before use.
7. Manufacturer & Marketing Authorization Holder
Manufacturer: Pharco Pharmaceuticals, Alexandria, Egypt. Public medicine references consistently identify Pharco Pharmaceuticals as the manufacturer of Otocalm.
Marketing Authorization Holder: A separately designated MAH distinct from the manufacturer could not be independently confirmed from the current public sources reviewed. Therefore, no separate company is identified here without documentary evidence.
8. Mechanism of Action
Phenazone: Phenazone is an analgesic of the pyrazolone group. Its analgesic effect has been associated with inhibition of cyclooxygenase-dependent prostaglandin synthesis, although the complete molecular basis of its analgesic action is not fully characterized. Reduction of prostaglandin-mediated sensitization of nociceptive pathways contributes to analgesia.
Chlorbutol: Chlorobutanol possesses antimicrobial activity against a range of microorganisms and has been described as having antibacterial and antifungal properties. It also has weak local anesthetic activity. The precise molecular basis of its antimicrobial effect is not as well characterized as that of conventional antibacterial drugs.
The combination therefore provides primarily local analgesic and antiseptic effects in the ear.
9. Spectrum of Activity
Chlorobutanol has antibacterial and antifungal activity, but Otocalm should not be regarded as a conventional topical antibiotic with a defined clinical antibacterial spectrum. It is primarily an analgesic/antiseptic otic preparation.
The available product information does not establish that Otocalm provides reliable treatment for a specific pathogen or that it can substitute for systemic or appropriately selected topical antimicrobial therapy when such treatment is clinically indicated.
10. Pharmacokinetics
There are no adequate publicly available pharmacokinetic data specifically describing systemic exposure to Otocalm administered as an otic preparation.
Systemic absorption from an intact tympanic membrane is considered unlikely, which is one reason the product information emphasizes use only when the tympanic membrane is intact. Consequently, systemic exposure after correct otic administration is expected to be limited.
Phenazone itself is systemically absorbed after oral or parenteral administration and undergoes hepatic metabolism, but pharmacokinetic findings from those routes should not be presented as quantitative pharmacokinetic parameters for Otocalm ear drops.
11. Indications
Otocalm is intended for symptomatic local relief of ear pain in selected ear conditions when the tympanic membrane is intact.
Product information for the Pharco preparation describes use in:
- Acute congestive otitis media.
- Bullous viral otitis.
- Barotraumatic otitis.
- Otic infections as an adjunct to systemic antibiotic treatment, when systemic antimicrobial therapy is clinically indicated.
The product should therefore be regarded primarily as a symptomatic analgesic/antiseptic preparation, rather than as definitive treatment for an underlying bacterial ear infection.
12. Administration
For the documented Otocalm regimen:
Adults and applicable patients: Instill 2–4 drops into the painful ear 2–3 times daily, allowing the solution to run along the ear canal wall, until pain improves or according to medical advice.
The bottle may be brought approximately to body temperature before administration to reduce discomfort caused by instilling cold liquid into the ear.
Use only in an ear with an intact tympanic membrane unless a qualified clinician specifically determines otherwise.
13. Method of Preparation
No preparation or reconstitution is required.
Otocalm is supplied as a ready-to-use otic solution in a dropper bottle. The solution should be administered directly into the ear according to the recommended directions.
Do not dilute the preparation or mix it with other ear drops unless specifically instructed by a healthcare professional.
14. Contraindications
Otocalm should not be used in:
- Known or suspected perforation of the tympanic membrane.
- Hypersensitivity to phenazone, chlorobutanol, or any component of the formulation.
Ear discharge should not simply be interpreted as an independent pharmacological contraindication. However, new or persistent otorrhea requires assessment because it may indicate tympanic membrane perforation or another condition in which these drops may be inappropriate.
15. Warnings & Precautions
Before administration, the integrity of the tympanic membrane should be established.
Administration through a perforated tympanic membrane may expose middle-ear structures and can result in adverse effects; consequently, the preparation should not be used when perforation is known or suspected.
Treatment should be discontinued and the ear reassessed if significant irritation, sensitization, or an allergic reaction develops.
Failure of symptoms to improve, worsening pain, persistent discharge, hearing deterioration, marked dizziness, or other concerning symptoms should prompt medical reassessment rather than prolonged self-treatment.
Otocalm is not a substitute for appropriate antimicrobial therapy when a clinically significant bacterial infection requires such treatment.
16. Drug Interactions
The product information reviewed reports no drug interactions for Otocalm.
Because systemic absorption from the ear is expected to be limited when the tympanic membrane is intact, clinically important systemic drug interactions are unlikely. Nevertheless, the absence of reported interactions should not be interpreted as proof that interactions are impossible, particularly when the tympanic membrane is not intact or when the preparation is used incorrectly.
17. Side Effects
Reported adverse effects are generally local and uncommon.
Possible reactions include:
- Local irritation.
- Burning or discomfort.
- Local allergic or hypersensitivity reactions.
- Hyperemia/redness of the ear canal.
Product information has described these local reactions as rare.
If irritation or sensitization develops, administration should be discontinued and the patient should be assessed if symptoms are significant or persistent.
18. Use in Special Populations
Children: Otocalm has been described in product information as being usable across patient populations, but dosing and the diagnosis of the underlying ear condition should be appropriate to the individual patient. In young children, particularly infants, medical assessment is preferable before treatment of significant ear pain.
Pregnancy: Product-specific evidence is limited. Some published product information states that use may be permitted when the tympanic membrane is intact because significant systemic absorption is considered unlikely. Nevertheless, pregnancy use should follow professional advice rather than routine self-medication.
Breastfeeding: It is not established from robust clinical data whether clinically relevant amounts reach breast milk. Because systemic absorption is expected to be low with an intact tympanic membrane, exposure is likely to be limited; however, use during breastfeeding should still follow professional advice.
Older adults: No specific age-related dosage adjustment has been established for the local otic use of Otocalm.
19. Storage Conditions
For the Egyptian product description reviewed:
Store at 15–30°C.
Keep the bottle tightly closed and out of the reach of children. Do not use after the expiry date stated on the package.
Storage instructions printed on the actual Egyptian package should take precedence if they differ from secondary references.
20. Additional Sections
Overdose
No clinically significant toxicity from local Otocalm overdose has been reported in the product information reviewed. Nevertheless, excessive or repeated administration should be avoided, particularly because the safety of administration through a perforated tympanic membrane is different from administration to an intact ear.
Use of the Dropper
Avoid allowing the dropper tip to contact the ear canal, fingers, or other surfaces unnecessarily, as contamination of the applicator can compromise product hygiene.
Nature of the Treatment
Otocalm provides symptomatic relief of ear pain and antiseptic activity. It does not establish the microbiological cause of an ear infection and should not be considered a universal treatment for otitis.
21. Frequently Asked Questions (FAQ)
What is Otocalm used for?
Otocalm is an otic analgesic/antiseptic preparation used for symptomatic relief of ear pain in selected conditions, particularly when the tympanic membrane is intact. It may also be used as an adjunct to systemic antibiotic therapy for appropriate otic infections.
What are the active ingredients in Otocalm?
It contains phenazone 5% w/w and chlorbutol 1% w/w.
Can Otocalm be used with a perforated eardrum?
No. Perforation of the tympanic membrane is a contraindication in the product information reviewed because otic administration may expose middle-ear structures to the preparation.
Can Otocalm treat an ear infection by itself?
It is primarily intended for symptomatic relief and antiseptic action. When an ear infection requires antibiotic treatment, Otocalm does not replace the appropriate antimicrobial therapy.
How many drops are used?
The documented regimen is 2–4 drops, 2–3 times daily, until pain improves or according to medical advice.
Does Otocalm require shaking before use?
No. It is supplied as a solution, rather than a suspension, so routine shaking is not required.
Can Otocalm cause irritation?
Yes. Local irritation and uncommon allergic or hypersensitivity reactions have been reported.
What should be done if ear discharge is present?
Ear discharge should be medically assessed rather than treated with Otocalm automatically, because discharge can be associated with tympanic membrane perforation or another condition requiring different management.
22. References
- Current Egyptian medicine listings for Otocalm Ear Drops 10 mL, identifying the product as Pharco, with chlorobutanol + phenazone and a 10 mL pack.
- Otocalm Ear Drops product information, documenting the 5% phenazone + 1% chlorbutol formulation and 10 mL presentation.
- Otocalm product information / published leaflet, including indications, contraindications, precautions, administration, pregnancy/lactation information, and adverse effects.
- Vademecum international product entry, identifying Otocalm 5% + 1% as an otic solution manufactured by Pharco Pharmaceuticals, Egypt, and classifying the combination under otological analgesic/anesthetic preparations.
- PubChem — Antipyrine (Phenazone), for substance identity and pharmacological information.
- PubMed — Pharmacokinetics and metabolism of antipyrine (phenazone), for general systemic pharmacokinetic information on phenazone by systemic routes.
- EMA scientific assessment concerning chlorobutanol, for safety-related information concerning chlorobutanol.
- Current product information for Otocalm, documenting the 2–4 drop, 2–3 times daily administration and precautions concerning tympanic membrane integrity.
Current Egyptian product identification: Otocalm Ear Drops 10 mL — Chlorobutanol + Phenazone — Pharco Pharmaceuticals.